Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same

A technology of adhesion molecules and binding fragments, applied in the direction of anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, receptor/cell surface antigen/cell surface determinant, animal cells, etc., can solve the therapeutic effect Insufficient and other problems, to achieve the effect of excellent specificity and affinity

Pending Publication Date: 2021-06-04
CARTEXELL INC
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In fact, ovarian cancer treatment using chimeric antigen receptor-expressing T cells specific for mesothelin, MUC16, and folate receptor, which are well-known factors associated with ovarian cancer, has been attempted , however, so far, treatment has been insufficiently effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
  • Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
  • Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0219] Example 1: Screening for scFv antibodies to L1 cell adhesion molecule antigens

[0220] 1.1. Human synthetic scFv phage display antibody library panning

[0221] In order to screen the anti-mL1 cell adhesion molecule scFv antibody that binds to the mouse L1 cell adhesion molecule (mouse L1 cell adhesion molecule, mL1 cell adhesion molecule) antigen, a human synthetic scFv phage display library (KscFv-1, KBIOHEALTH ) 4 rounds of phage panning for the antigen mL1 cell adhesion molecule protein ( figure 1 ). Antigen mL1 cell adhesion molecule protein (R&D system, Cat No. 5674-NC) was added to the immunotube (immunotube), cultured at 4°C overnight, and then, 5% skim milk (skim milk) was used to Phosphate buffered saline (MPBS) was reacted at room temperature for 1 hour, and the blocking process was carried out. A phosphate buffer solution containing skim milk was added to KscFv-1, and reacted at room temperature for 1 hour to prepare blocked phage. The blocked phages we...

Embodiment 2

[0280] Example 2. Anti-L1 Cell Adhesion Molecule-Chimeric Antigen Receptor Gene Expression T Cell Preparation and Efficacy Confirmation

[0281] 2.1. Anti-L1 cell adhesion molecule-chimeric antigen receptor gene ensures

[0282] 2.1.1. Ensuring anti-mL1 cell adhesion molecule scFv antibody gene

[0283] Anti-L1 cells were ensured from the cloned phagemids containing the anti-L1 cell adhesion molecule scFv screened in the present invention by sequence analysis using the Lac promoter-forward primer (Lac promoter-forward primer). Base sequences of adhesion molecule scFv clones (Table 5). Based on the base sequence analyzed, a forward primer and a reverse primer were prepared, and the above-mentioned phagemid was used as a template to amplify by the polymerase chain reaction method to ensure the polymerase chain reaction. reaction product. Using the polymerase chain reaction product of the secured anti-L1 cell adhesion molecule scFv antibody as a template, the primers of sequen...

Embodiment 3

[0322] Example 3. Confirmation of efficacy (in vivo) of anti-L1 cell adhesion molecule-chimeric antigen receptor gene expressing T cells in vivo

[0323] In order to confirm the anticancer activity of anti-L1 cell adhesion molecule-chimeric antigen receptor gene-expressing T cells in vivo, a cancer-induced animal model was used. In the subcutaneous (subcutaneous, SC) subcutaneous (subcutaneous, SC) administration of 3 × 10 NOD / SCID mice (7 weeks old, female) lacking T cells, B cells, natural killer cells (NK cells) 6 Individual SKOV3 cancer cells (Target, T) mixed with Matrigel (Matrigel) at a ratio of 1:1 were used to induce cancer. Three days after cancer cell administration, two L1-chimeric antigens whose efficacy was confirmed in vitro as anti-L1 cell adhesion molecule-chimeric antigen receptor expressing T cells were administered once a day to each NOD / SCID mouse Receptor-002 and L1-Chimeric Antigen Receptor-004 and the T cells of the control group were administered 3 ti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an anti-L1CAM antibody specifically binding to L1CAM antigen or an antigen-binding fragment thereof, a chimeric antigen receptor comprising the same, and uses thereof. The anti-L1CAM antibody or the antigen-binding fragment of the present invention is excellent in specificity and affinity to L1CAM and thus may be used in the treatment and diagnosis of cancers related to high expression of L1CAM and diseases related to inflammatory disorders. In particular, when the chimeric antigen receptor comprising the anti-L1CAM antibody of the present invention is expressed in effector cells such as T lymphocytes, the chimeric antigen receptor may be effectively used as immunotherapy for cancers related to L1CAM and inflammatory disorders.

Description

technical field [0001] This invention was completed by the project number 2016M3A9D3021340 under the support of the Ministry of Future Creation and Science of Korea. The research and management agency of the above project is the Korea Research Foundation, and the name of the research business is "Biomedical Technology Research and Development Project (New Generation Biology) Immune Mechanism Control Technology Research and Development ", the name of the research project is "Research on Multifunctional Fusion T Cell Therapy Using Chimeric Antigen Receptors and B Cells", the competent institution is the Seoul National University Industry-University Cooperation Group, and the research time is from May 01, 2016 to 2021 January 31. [0002] This application claims priority from Korean Patent Application No. 10-2018-0125538 filed on October 19, 2018, the entire contents of which are incorporated herein by reference. [0003] The present invention relates to an anti-L1 cell adhesion...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K14/705C12N5/0783C12N15/86A61P1/00A61P29/00A61P35/00
CPCA61P1/00A61P29/00A61P35/00C07K14/7051C07K2319/03A61K2039/5156A61K39/001166C12N2740/13043C07K16/2803C07K2317/565C07K2317/24C07K2317/56C07K2317/622C12N5/0636C12N2510/00A61K35/17C07K14/70521C12N15/86C07K2317/53C07K2317/567C07K14/70514C07K14/70517C07K14/70532C07K14/70575C07K14/70589C07K14/7151
Inventor J-A·陈郑在均金大荣Y·J·金B·宇
Owner CARTEXELL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com